We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

559 hedge funds and large institutions have $11.4B invested in Abiomed Inc in 2019 Q1 according to their latest regulatory filings, with 88 funds opening new positions, 213 increasing their positions, 188 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 53

13% more repeat investments, than reductions

Existing positions increased: 213 | Existing positions reduced: 188

6% more funds holding

Funds holding: 529559 (+30)

11% less capital invested

Capital invested by funds: $12.8B → $11.4B (-$1.45B)

45% less call options, than puts

Call options by funds: $165M | Put options by funds: $300M

54% less funds holding in top 10

Funds holding in top 10: 136 (-7)

Holders
559
Holders Change
+30
Holders Change %
+5.67%
% of All Funds
12.1%
Holding in Top 10
6
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-53.85%
% of All Funds
0.13%
New
88
Increased
213
Reduced
188
Closed
53
Calls
$165M
Puts
$300M
Net Calls
-$135M
Net Calls Change
-$50.5M
Name Holding Trade Value Shares
Change
Change in
Stake
LOAMS
151
Lombard Odier Asset Management (Switzerland)
Switzerland
$6.43M +$7.48M +22,500 New
SAM
152
Sectoral Asset Management
Quebec, Canada
$6.41M
Asset Management One
153
Asset Management One
Japan
$6.27M -$15.3M -46,012 -68%
AIM
154
Allen Investment Management
New York
$6.26M +$14.3K +43 +0.2%
PAMU
155
Pictet Asset Management (UK)
United Kingdom
$5.98M +$46.5K +140 +0.7%
GIM
156
Granahan Investment Management
Massachusetts
$5.94M +$4.43M +13,334 +179%
MSL
157
Mackay Shields LLC
New York
$5.91M -$76.4K -230 -1%
SCM
158
Stevens Capital Management
Pennsylvania
$5.87M +$1.93M +5,795 +39%
Jane Street
159
Jane Street
New York
$5.84M +$3.19M +9,590 +88%
SI
160
Stephens Inc
Arkansas
$5.58M -$50.2K -151 -0.8%
AAM
161
Advisors Asset Management
Colorado
$5.37M -$433K -1,304 -6%
KBC Group
162
KBC Group
Belgium
$5.35M -$758K -2,281 -11%
VRS
163
Virginia Retirement Systems
Virginia
$5.34M +$2.46M +7,400 +65%
NIP
164
Nicholas Investment Partners
California
$5.32M -$3.11M -9,360 -33%
Parallax Volatility Advisers
165
Parallax Volatility Advisers
California
$5.09M +$5.57M +16,763 +1,583%
BCIM
166
British Columbia Investment Management
British Columbia, Canada
$5.04M -$753K -2,265 -11%
Royal London Asset Management
167
Royal London Asset Management
United Kingdom
$4.99M
Treasurer of the State of North Carolina
168
Treasurer of the State of North Carolina
North Carolina
$4.86M +$51.5K +155 +0.9%
Wolverine Trading
169
Wolverine Trading
Illinois
$4.84M -$496K -1,492 -8%
AIG
170
American International Group
New York
$4.83M -$47.5K -143 -0.8%
TI
171
Trexquant Investment
Connecticut
$4.8M +$5.59M +16,813 New
Lord, Abbett & Co
172
Lord, Abbett & Co
New Jersey
$4.73M +$137K +412 +3%
Wellington Management Group
173
Wellington Management Group
Massachusetts
$4.61M +$4.85M +14,583 +930%
Aviva
174
Aviva
United Kingdom
$4.6M +$40.5K +122 +0.8%
SG Americas Securities
175
SG Americas Securities
New York
$4.52M +$3.13M +9,415 +147%

ABMD Hedge Fund Activity: Q1 2019 in Review

559 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q1 2019, worth a combined $11.4B — down 11% from $12.8B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ABMD positions and 53 closed out — a net gain of 35 holders — while 213 added to existing stakes and 188 trimmed.

The largest buyer was Amundi Asset Management US, adding an estimated $163M. The largest seller was Winslow Capital Management, exiting entirely with an estimated $170M sold.

  • 559 institutional investors held Abiomed Inc (ABMD) as of Q1 2019, up from 529 in Q4 2018.
  • Funds reported $11.4B of Abiomed Inc stock for Q1 2019, down 11% quarter-over-quarter.
  • 88 funds opened new Abiomed Inc positions in Q1 2019 and 53 closed out, a net change of +35 holders.
  • The largest Abiomed Inc buyer in Q1 2019 was Amundi Asset Management US, an estimated $163M added.
  • The largest Abiomed Inc seller in Q1 2019 was Winslow Capital Management, an estimated $170M sold.

Based on aggregated 13F filings for Q1 2019.